Literature DB >> 29903589

[Corneal collagen cross-linking to treat infectious keratitis].

R Atia1, L Jouve1, J Knoeri1, C Georgeon1, L Laroche2, V Borderie2, N Bouheraoua3.   

Abstract

Infectious keratitis are a frequent cause of ocular morbidity. Today, new treatments are necessary to combat the emergence of antibiotic resistant germs. Corneal collagen cross-linking has been suggested to treat corneal infectious (PACK-CXL). Its action would be both antimicrobial and protective for the cornea, increasing its biochemical resistence to proteolytic enzymes. In vivo, PACK-CXL might demonstrate good efficacy against bacterial keratitis, contrary to herpetic keratitis for which it is contraindicated. For fungal or amoebic keratitis, results are uncertain regarding its safety and efficacy. The purpose of this paper is to clarify the use of corneal collagen cross-linking to treat infectious keratitis.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cornea; Corneal collagen cross-linking; Cornée; Cross-linking du collagène; Infectious keratitis; Kératite infectieuse; PACK-CXL

Mesh:

Substances:

Year:  2018        PMID: 29903589     DOI: 10.1016/j.jfo.2017.12.007

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis.

Authors:  Carolina Nunes da Silva; Flavia Rodrigues da Silva; Lays Fernanda Nunes Dourado; Pablo Victor Mendes Dos Reis; Rummenigge Oliveira Silva; Bruna Lopes da Costa; Paula Santos Nunes; Flávio Almeida Amaral; Vera Lúcia Dos Santos; Maria Elena de Lima; Armando da Silva Cunha Júnior
Journal:  Toxins (Basel)       Date:  2019-04-04       Impact factor: 4.546

Review 2.  Infectious Keratitis: An Update on Role of Epigenetics.

Authors:  Sudhir Verma; Aastha Singh; Akhil Varshney; R Arun Chandru; Manisha Acharya; Jyoti Rajput; Virender Singh Sangwan; Amit K Tiwari; Tuhin Bhowmick; Anil Tiwari
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.